MBNL1 and myotonic dystrophy type 1: Main criteria to evaluate the efficacy of the identified small molecules included prevention of MBNL1 binding to the expanded CUG repeats, reduction in CUG foci and correction of splicing targets, known to be misregulated in DM1 using cell culture lines from patients with DM1 or DM1 mice.